Hypertension in the Elderly

Statistics by country, region and WHO mortality. WHO Statistical Information System [online]. Available from URL: http://www3.who.int/whosis/menu.cfm [Accessed 2005 Apr 1] Ogihara T, Hiwada K, Morimoto S, et al. Guidelines for treatment of hypertension in the elderly. Hypertens Res 2003; 26: 1–36 Hiwada K, Ogihara T, Matsumoto M, et al. Guidelines for hypertension in the elderly: Ministry of Health and Welfare of Japan. Hypertens Res 1999; 22: 231–59 Kaplan NM. Hypertension in the elderly. 2nd ed. London: Martin Dunitz, 2002 National High Blood Pressure Education Program Working Group. National High Blood Pressure Education Program Working Group report on hypertension in the elderly. Hypertension 1994; 23: 275–85 Madhavan S, Ooi WL, Cohen H, et al. Relation of pulse pressure and blood pressure reduction to the incidence of myocardial infarction. Hypertension 1994; 23: 395–401 O’Rourke M. Mechanical principles in arterial disease. Hypertension 1995; 26: 2–9 Benetos A, Zureik M, Morcet J, et al. A decrease in diastolic blood pressure combined with an increase in systolic blood pressure is associated with a higher cardiovascular mortality in men. J Am Coll Cardiol 2000; 35: 673–80 Franklin SS, Khan SA, Wong ND, et al. Is pulse pressure useful in predicting risk for coronary heart disease? The Framingham Heart Study. Circulation 1999; 100: 354–60 Blacher J, Staessen JA, Girerd X, et al. Pulse pressure not mean pressure determines cardiovascular risk in older hypertensive patients. Arch Intern Med 2000; 160: 1085–9 Lewington S, Clarke R, Qizilbash N, et al. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–13 Arima H, Tanizaki Y, Kiyohara Y, et al. Validity of the JNC VI recommendations for the management of hypertension in a general population of Japanese elderly: the Hisayama study. Arch Intern Med 2003; 163: 361–6 SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension: final results of the Systolic Hypertension in the Elderly Program (SHEP). JAMA 1991; 265: 3255–64 Gong L, Zhang W, Zhu Y, et al. Shanghai Trial Of Nifedipine in the Elderly (STONE). J Hypertens 1996; 14: 1237–45 Amery A, Birkenhager W, Brixko P, et al. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985; 1: 1349–54 Coope J, Warrender TS. Randomised trial of treatment of hypertension in elderly patients in primary care. BMJ (Clin Res Ed) 1986; 293: 1145–51 Dahlof B, Lindholm LH, Hansson L, et al. Morbidity and mortality in the Swedish Trial in Old Patients with Hypertension (STOP-Hypertension). Lancet 1991; 338: 1281–5 MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. BMJ 1992; 304: 405–12 Staessen JA, Fagard R, Thijs L, et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension: the Systolic Hypertension in Europe (Syst-Eur) Trial Investigators. Lancet 1997; 350: 757–64 Liu L, Wang JG, Gong L, et al. Comparison of active treatment and placebo in older Chinese patients with isolated systolic hypertension: Systolic Hypertension in China (Syst-China) Collaborative Group. J Hypertens 1998; 16: 1823–9 Chobanian AV, Roccella EJ. The JNC-7 guidelines and the optimal target for systolic blood pressure [letter]. Hypertension 2004; 43: e31 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension. J Hypertens 2003; 21: 1983–92 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011–53 Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidelines for the management of hypertension for general practitioners. Hypertens Res 2001; 24: 613–34 Imai Y, Nishiyama A, Ohkubo T, et al. Factors affecting the nocturnal decrease in blood pressure: a community-based study in Ohasama. J Hypertens 1997; 15: 827–38 Staessen JA, Thijs L, Fagard R, et al. Predicting cardiovascular risk using conventional vs ambulatory blood pressure in older patients with systolic hypertension: Systolic Hypertension in Europe Trial Investigators. JAMA 1999; 282: 539–46 Kario K, Pickering TG, Umeda Y, et al. Morning surge in blood pressure as a predictor of silent and clinical cerebrovascular disease in elderly hypertensives: a prospective study. Circulation 2003; 107: 1401–6 Bobrie G, Chatellier G, Genes N, et al. Cardiovascular prognosis of ‘masked hypertension’ detected by blood pressure self-measurement in elderly treated hypertensive patients. JAMA 2004; 291: 1342–9 Imai Y, Otsuka K, Kawano Y, et al. Japanese Society of Hypertension (JSH) guidelines for self-monitoring of blood pressure at home. Hypertens Res 2003; 26: 771–82 Chobanian AV, Bakris GL, Black HR, et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206–52 Williams B, Poulter NR, Brown MJ, et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV. J Hum Hypertens 2004; 18: 139–85 Japanese Society of Hypertension Guidelines Subcommittee for the Management of Hypertension. Guidlines for the management of hypertension (JSH2004) [in Japanese]. Tokyo: Life Science, 2004 Ohkubo T, Imai Y, Tsuji I, et al. Home blood pressure measurement has a stronger predictive power for mortality than does screening blood pressure: a population-based observation in Ohasama, Japan. J Hypertens 1998; 16: 971–5 Suzuki Y, Kuwajima I, Aono T, et al. Prognostic value of nighttime blood pressure in the elderly: a prospective study of 24-hour blood pressure. Hypertens Res 2000; 23: 323–30 Kaplan NM. Renal vascular hypertension. In: Clinical hypertension. 7th ed. Baltimore (MD): Williams and Wilkins, 1998: 303–6 Insua JT, Sacks HS, Lau TS, et al. Drug treatment of hypertension in the elderly: a meta-analysis. Ann Intern Med 1994; 121: 355–62 Staessen JA, Gasowski J, Wang JG, et al. Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 2000; 355: 865–72 Gueyffier F, Bulpitt C, Boissel JP, et al. Antihypertensive drugs in very old people: a subgroup meta-analysis of randomised controlled trials: INDANA Group. Lancet 1999; 353: 793–6 Bulpitt CJ, Beckett NS, Cooke J, et al. Results of the pilot study for the Hypertension in the Very Elderly Trial. J Hypertens 2003; 21: 2409–17 Bulpitt C, Fletcher A, Beckett N, et al. Hypertension in the Very Elderly Trial (HYVET): protocol for the main trial. Drugs Aging 2001; 18: 151–64 National Intervention Cooperative Study in Elderly Hypertensives Study Group. Randomized double-blind comparison of a calcium antagonist and a diuretic in elderly hypertensives. Hypertension 1999; 34: 1129–33 Black HR, Elliott WJ, Weber MA, et al. One-year study of felodipine or placebo for stage 1 isolated systolic hypertension. Hypertension 2001; 38: 1118–23 Somes GW, Pahor M, Shorr RI, et al. The role of diastolic blood pressure when treating isolated systolic hypertension. Arch Intern Med 1999; 159: 2004–9 Perry Jr HM, Davis BR, Price TR, et al. Effect of treating isolated systolic hypertension on the risk of developing various types and subtypes of stroke: the Systolic Hypertension in the Elderly Program (SHEP). JAMA 2000; 284: 465–71 Kjeldsen SE, Kolloch RE, Leonetti G, et al. Influence of gender and age on preventing cardiovascular disease by antihypertensive treatment and acetylsalicylic acid: the HOT study. Hypertension Optimal Treatment. J Hypertens 2000; 18: 629–42 Ogihara T. Practitioner’s Trial on the Efficacy of Antihypertensive Treatment in the Elderly Hypertension (The PATE-Hypertension Study) in Japan. Am J Hypertens 2000; 13: 461–7 Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–97 Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients: the Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–53 Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033–41 Wing LM, Reid CM, Ryan P, et al. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583–92 Kjeldsen SE, Dahlof B, Devereux RB, et al. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan Intervention for Endpoint Reduction (LIFE) sub-study. JAMA 2002; 288: 1491–8 Brown MJ, Palmer CR, Castaigne A, et al. Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a Goal in Hypertension Treatment (INSIGHT). Lancet 2000; 356: 366–72 Lithell H, Hansson L, Skoog I, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2003; 21: 875–86 Wollner L, McCarthy ST, Soper ND, et al. Failure of cerebral autoregulation as a cause of brain dysfunction in the elderly. Br J Med 1979; 1: 1117–8 Tsujimoto G, Hashimoto K, Hoffman BB. Pharmacokinetic and pharmacodynamic principles of drug therapy in old age. Int J Clin Pharmacol Ther Toxicol 1989; 27(Pt 1): 13–26 Friedman JR, Norman DC, Yoshikawa TT. Correlation of estimated renal function parameters versus 24-hour creatinine clearance in ambulatory elderly. J Am Geriatr Soc 1989; 37: 145–9 Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure: age and pressure over time. Hypertension 1991; 18: 67–71 Whelton PK, Appel LJ, Espeland MA, et al. Sodium reduction and weight loss in the treatment of hypertension in older persons: a randomized controlled trial of nonpharmacologic interventions in the elderly (TONE): TONE Collaborative Research Group. JAMA 1998; 279: 839–46 Cutler JA, Follmann D, Allender PS. Randomized trials of sodium reduction: an overview. Am J Clin Nutr 1997; 65: 643S–651S Fujita T, Ando K. Hemodynamic and endocrine changes associated with potassium supplementation in sodium-loaded hypertensives. Hypertension 1984; 6: 184–92 Juurlink DN, Mamdani MM, Lee DS, et al. Rates of hyperkalemia after publication of the Randomized Aldactone Evaluation Study. N Engl J Med 2004; 351: 543–51 McCarron DA, Morris CD, Henry HJ, et al. Blood pressure and nutrient intake in the United States. Science 1984; 224: 1392–8 Joffres MR, Reed DM, Yano K. Relationship of magnesium intake and other dietary factors to blood pressure: the Honolulu heart study. Am J Clin Nutr 1987; 45: 469–75 Kawano Y, Matsuoka H, Takishita S, et al. Effects of magnesium supplementation in hypertensive patients: assessment by office, home, and ambulatory blood pressures. Hypertension 1998; 32: 260–5 The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1997; 157: 2413–46 Ueshima H, Ozawa H, Baba S, et al. Alcohol drinking and high blood pressure: data from a 1980 national cardiovascular survey of Japan. J Clin Epidemiol 1992; 45: 667–73 Lee TK, Huang ZS, Ng SK, et al. Impact of alcohol consumption and cigarette smoking on stroke among the elderly in Taiwan. Stroke 1995; 26: 790–4 Motoyama M, Sunami Y, Kinoshita F, et al. Blood pressure lowering effect of low intensity aerobic training in elderly hypertensive patients. Med Sci Sports Exerc 1998; 30: 818–23 Physical exercise in the management of hypertension: a consensus statement by the World Hypertension League. J Hypertens 1991; 9: 283–7 Pratley RE, Hagberg JM, Dengel DR, et al. Aerobic exercise training-induced reductions in abdominal fat and glucose-stimulated insulin responses in middle-aged and older men. J Am Geriatr Soc 2000; 48: 1055–61 Kinoshita M, Nakaya Y, Harada N, et al. Combination therapy of exercise and angiotensin-converting enzyme inhibitor markedly improves insulin sensitivities in hypertensive patients with insulin resistance. Circ J 2002; 66: 655–58 Rinder MR, Spina RJ, Peterson LR, et al. Comparison of effects of exercise and diuretic on left ventricular geometry, mass, and insulin resistance in older hypertensive adults. Am J Physiol Regul Integr Comp Physiol 2004; 287(2): R360–8 Messerli FH, Grossman E, Goldbourt U. Are beta-blockers efficacious as first-line therapy for hypertension in the elderly?: a systematic review. JAMA 1998; 279: 1903–7 Ogihara T, Kuramoto K. Effect of long-term treatment with antihypertensive drugs on quality of life of elderly patients with hypertension: a double-blind comparative study between a calcium antagonist and a diuretic. NICS-EH Study Group: National Intervention Cooperative Study in Elderly Hypertensives. Hypertens Res 2000; 23: 33–7 Hansson L, Lindholm LH, Ekbom T, et al. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 Study. Lancet 1999; 354: 1751–6 Chaudhry SI, Krumholz HM, Foody JM. Systolic hypertension in older persons. JAMA 2004; 292(9): 1074–80 ALLHAT Collaborative Research Group. Major cardiovascular events in hypertensive patients randomized to doxazosin vs chlorthalidone: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2000; 283: 1967–75 Cai H, Yao H, Ibayashi S, et al. Amlodipine: a Ca2+ channel antagonist, modifies cerebral blood flow autoregulation in hypertensive rats. Eur J Pharmacol 1996; 313(1–2): 103–6 Sadoshima S, Nagao T, Ibayashi S, et al. Inhibition of angiotensin-converting enzyme modulates the autoregulation of regional cerebral blood flow in hypertensive rats. Hypertension 1994; 23(6 Pt 1): 781–5 Vraamark T, Waldemar G, Strandgaard S, et al. Angiotensin II receptor antagonist CV-11974 and cerebral blood flow autoregulation. J Hypertens 1995; 13(7): 755–61 A randomized trial of propranolol in patients with acute myocardial infarction. I: mortality results. JAMA. 1982; 247: 1707–14 Dargie HJ. Effect of carvedilol on outcome after myocardial infarction in patients with left-ventricular dysfunction: the CAPRICORN randomised trial. Lancet 2001; 357: 1385–90 Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. The SAVE Investigators. N Engl J Med 1992; 327: 669–77 Pitt B, Remme W, Zannad F, et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003; 348: 1309–21 Pfeffer MA, McMurray JJ, Velazquez EJ, et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003; 349: 1893–906 Japanese Beta-Blockers and Calcium Antagonists Myocardial Infarction (JBCMI) Investigators. Comparison of the effects of beta blockers and calcium antagonists on cardiovascular events after acute myocardial infarction in Japanese subjects. Am J Cardiol 2004; 93: 969–73 White HD. Candesartan and heart failure: the allure of CHARM. Lancet 2003; 362: 754–5 McMurray JJ, Ostergren J, Swedberg K, et al. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-con-verting-enzyme inhibitors: the CHARM-Added trial. Lancet 2003; 362: 767–71 Pfeffer MA, Swedberg K, Granger CB, et al. Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet 2003; 362: 759–66 Packer M, Bristow MR, Cohn JN, et al. The effect of carvedilol on morbidity and mortality in patients with chronic heart failure: U.S. Carvedilol Heart Failure Study Group. N Engl J Med 1996; 334(21): 1349–55 Williams BR, Kim J. Cardiovascular drug therapy in the elderly: theoretical and practical considerations. Drugs Aging 2003; 20(6): 445–63 Rich MW. Therapy for acute myocardial infarction. Clin Geriatr Med 1996; 12(1): 141–68 Owen A. Experience of commencing carvedilol in elderly patients with heart failure in a routine outpatient clinic. Eur J Heart Fail 2000; 2(3): 287–9 Palazzuoli A, Bruni F, Puccetti L, et al. Effects of carvedilol on left ventricular remodeling and systolic function in elderly patients with heart failure. Eur J Heart Fail 2002; 4(6): 765–70 UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703–13 Lindholm LH, Ibsen H, Dahlof B, et al. Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 1004–10 Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes and systolic hypertension: Systolic Hypertension in Europe Trial Investigators. N Engl J Med 1999; 340: 677–84 Ravid M, Savin H, Jutrin I, et al. Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 1993; 118(8): 577–81 Iimura O, Shimamoto K, Matsuda K, et al. Effects of angiotensin receptor antagonist and angiotensin converting enzyme inhibitor on insulin sensitivity in fructose-fed hypertensive rats and essential hypertensives. Am J Hypertens 1995; 8 (4 Pt 1): 353–7 Goyal RK. Hyperinsulinemia and insulin resistance in hypertension: differential effects of antihypertensive agents. Clin Exp Hypertens 1999; 21(1–2): 167–79 Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995–1003 Lindeman RD, Tobin JD, Shock NW. Association between blood pressure and the rate of decline in renal function with age. Kidney Int 1984; 26(6): 861–8 Fernandez-Vega F, Abellan J, Sanz de Castro S, et al. A study on the efficacy and safety of losartan in elderly patients with mild to moderate essential hypertension. Int Urol Nephrol 2001; 32(4): 519–23 Narita T, Kakei M, Ito S. Aggressive antihypertensive treatment and serum lipid lowering therapy are necessary to prevent deterioration of the renal function even in elderly type 2 diabetic patients with persistent albuminuria. Gerontology 2002; 48(5): 302–8 Fliser D, Ritz E. Relationship between hypertension and renal function and its therapeutic implications in the elderly. Gerontology 1998; 44(3): 123–31 Abdi R, Brenner BM. Impact of renin angiotensin system blockade on renal function in health and disease: an end or a beginning? Semin Nephrol 2004; 24(2): 141–6 Bitar R, Flores O, Reverte M, et al. Beneficial effect of verapamil added to chronic ACE inhibitor treatment on renal function in hypertensive elderly patients. Int Urol Nephrol 2000; 32(2): 165–9